MX2022000080A - Antagonistas de receptor del factor de liberacion de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congenita. - Google Patents
Antagonistas de receptor del factor de liberacion de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congenita.Info
- Publication number
- MX2022000080A MX2022000080A MX2022000080A MX2022000080A MX2022000080A MX 2022000080 A MX2022000080 A MX 2022000080A MX 2022000080 A MX2022000080 A MX 2022000080A MX 2022000080 A MX2022000080 A MX 2022000080A MX 2022000080 A MX2022000080 A MX 2022000080A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor antagonists
- treatment
- crf1 receptor
- adrenal hyperplasia
- congenital adrenal
- Prior art date
Links
- 108091005471 CRHR1 Proteins 0.000 title abstract 2
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 208000005676 Adrenogenital syndrome Diseases 0.000 title 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract 1
- 239000003098 androgen Substances 0.000 abstract 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 abstract 1
- 229960000258 corticotropin Drugs 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 238000010606 normalization Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Antagonistas de receptor de CRF1 tienen el potencial para inhibir directamente liberación de ACTH en pacientes con CAH y por lo mismo permitir normalización de producción de andrógenos mientras que se usan dosis menores, más fisiológicas de hidrocortisona, y de esta forma reduciendo efectos laterales asociados a tratamiento.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461929941P | 2014-01-21 | 2014-01-21 | |
US201461981033P | 2014-04-17 | 2014-04-17 | |
US201462069155P | 2014-10-27 | 2014-10-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022000080A true MX2022000080A (es) | 2022-02-03 |
Family
ID=52450623
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016009499A MX2016009499A (es) | 2014-01-21 | 2015-01-21 | Antagonista de receptor del factor de liberacion de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congenita. |
MX2021012539A MX2021012539A (es) | 2014-01-21 | 2016-07-21 | Antagonistas de receptor del factor de liberacion de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congenita. |
MX2022000080A MX2022000080A (es) | 2014-01-21 | 2016-07-21 | Antagonistas de receptor del factor de liberacion de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congenita. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016009499A MX2016009499A (es) | 2014-01-21 | 2015-01-21 | Antagonista de receptor del factor de liberacion de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congenita. |
MX2021012539A MX2021012539A (es) | 2014-01-21 | 2016-07-21 | Antagonistas de receptor del factor de liberacion de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congenita. |
Country Status (13)
Country | Link |
---|---|
US (5) | US20170020877A1 (es) |
EP (1) | EP3096756B1 (es) |
JP (4) | JP6585625B2 (es) |
KR (2) | KR102258522B1 (es) |
CN (2) | CN106102740A (es) |
AU (3) | AU2015209452C1 (es) |
BR (1) | BR112016016975B1 (es) |
CA (2) | CA2936974A1 (es) |
IL (4) | IL296683B2 (es) |
MX (3) | MX2016009499A (es) |
NZ (1) | NZ722122A (es) |
RU (1) | RU2718918C2 (es) |
WO (1) | WO2015112642A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3096756B1 (en) * | 2014-01-21 | 2024-06-12 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
WO2015127288A1 (en) | 2014-02-20 | 2015-08-27 | Alder Biopharmaceuticals, Inc. | Anti-acth antibodies and use thereof |
EP3510029A4 (en) | 2016-09-07 | 2020-03-11 | The Regents of The University of California | ALLOSTERIC CORTICOTROPIN RELEASING FACTOR-1 (CRFR1) ANTAGONISTS TO REDUCE P-TAU AND IMPROVE THE COGNITION |
CN110996943A (zh) | 2017-08-14 | 2020-04-10 | 云杉生物科学公司 | 促肾上腺皮质激素释放因子受体拮抗剂 |
EP3784233B1 (en) * | 2018-04-27 | 2024-06-05 | Spruce Biosciences, Inc. | Methods for treating testicular and ovarian adrenal rest tumors |
MA54395A (fr) * | 2018-12-07 | 2022-03-16 | Neurocrine Biosciences Inc | Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale |
JP2022000473A (ja) * | 2018-12-07 | 2022-01-04 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | 先天性副腎過形成を処置するためのcrf1受容体アンタゴニスト、その医薬製剤および固体形態 |
EP3986416A4 (en) * | 2019-07-19 | 2023-06-28 | Spruce Biosciences, Inc. | Methods of treating congenital adrenal hyperplasia |
WO2021062246A1 (en) * | 2019-09-27 | 2021-04-01 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
WO2021252669A1 (en) * | 2020-06-10 | 2021-12-16 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia |
AU2021324839B2 (en) * | 2020-08-12 | 2024-02-29 | Spruce Biosciences, Inc. | Methods and compositions for treating polycystic ovary syndrome |
MD20210019A2 (ro) | 2021-04-12 | 2022-10-31 | Максим МАСЮТИН | Metodă de tratament a hiperplaziei suprarenale congenitale, cauzate de deficit de 21-hidroxilază cu debut tardiv prin regimul de glucocorticoizi adaptat individual |
US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4949582B1 (es) | 1969-01-20 | 1974-12-27 | ||
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
FR2692893B1 (fr) | 1992-06-24 | 1994-09-02 | Sanofi Elf | Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
US6664261B2 (en) | 1996-02-07 | 2003-12-16 | Neurocrine Biosciences, Inc. | Pyrazolopyrimidines as CRF receptor antagonists |
TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
CA2265672C (en) | 1996-09-16 | 2008-12-02 | Du Pont Pharmaceuticals Company | Pyrazinones and triazinones and their derivatives thereof |
FR2754258B1 (fr) | 1996-10-08 | 1998-12-31 | Sanofi Sa | Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
DK0977737T3 (da) | 1997-04-22 | 2004-01-26 | Janssen Pharmaceutica Nv | CRF-antagonistisk quino- og quinazoline |
WO1999010350A1 (en) | 1997-08-22 | 1999-03-04 | Du Pont Pharmaceuticals Company | NITROGEN SUBSTITUTED IMIDAZO[4,5-c]PYRAZOLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS |
US6531475B1 (en) | 1998-11-12 | 2003-03-11 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
JP2003528802A (ja) | 1999-04-02 | 2003-09-30 | ニューロゲン コーポレイション | N−ベンゾイミダゾリルメチル−及びn−インドリルメチル−ベンズアミド並びにcrf調節物質としてのそれらの使用 |
FR2796380B3 (fr) | 1999-07-15 | 2001-08-17 | Sanofi Synthelabo | Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant |
FR2802530B1 (fr) | 1999-12-17 | 2002-02-22 | Sanofi Synthelabo | Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant |
WO2003006015A1 (en) | 2001-07-13 | 2003-01-23 | Bristol-Myers Squibb Pharma Company | Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands |
KR20060110006A (ko) | 2004-02-13 | 2006-10-23 | 화이자 프로덕츠 인크. | 비전형 항정신병제와 코르티코트로핀 방출 인자 길항제의치료적 조합물 |
US20060078623A1 (en) | 2004-08-13 | 2006-04-13 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
GB0519957D0 (en) | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
EP1802621B1 (en) | 2004-10-19 | 2009-05-06 | SmithKline Beecham (Cork) Limited | Crf receptor antagonists and methods relating thereto |
SI1869049T1 (sl) | 2005-03-21 | 2009-08-31 | Lilly Co Eli | Spojine imidazopiridazina |
WO2006107784A1 (en) | 2005-04-05 | 2006-10-12 | Eli Lilly And Company | Imidazopyridazine compounds |
TWI370820B (en) | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
JPWO2006126718A1 (ja) | 2005-05-27 | 2008-12-25 | 田辺三菱製薬株式会社 | ピラゾロピリミジン誘導体 |
EP2361619A1 (en) | 2005-11-10 | 2011-08-31 | TopoTarget UK Limited | Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer |
EP1961745A1 (en) | 2005-12-12 | 2008-08-27 | Ono Pharmaceutical Co., Ltd. | Bicyclic heterocyclic compound |
EP1961754A4 (en) | 2005-12-15 | 2009-11-11 | Ono Pharmaceutical Co | BICYCLIC HETEROCYCLIC COMPOUND |
ES2435793T3 (es) | 2006-02-07 | 2013-12-23 | Phenoquest Ag | Procedimientos para el tratamiento de trastornos afectivos |
EP1834641A1 (en) | 2006-03-16 | 2007-09-19 | Sanofi-Aventis | Use of CRF1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia |
AU2007253684A1 (en) | 2006-05-22 | 2007-11-29 | Vanda Pharmaceuticals, Inc. | Treatment for depressive disorders |
EA016056B1 (ru) | 2006-09-20 | 2012-01-30 | Эли Лилли Энд Компани | Тиофенпиразолопиримидиновые соединения |
RS51545B (en) * | 2006-09-20 | 2011-06-30 | Eli Lilly And Company | THIAZOL PIRAZOLOPIRAMIDINS AS ANTAGONISTS OF CRF1 RECEPTORS |
EP2088861A4 (en) | 2006-10-25 | 2010-07-07 | Takeda Pharmaceutical | BENZIMIDAZOLE COMPOUNDS |
WO2008083070A1 (en) | 2006-12-29 | 2008-07-10 | Neurogen Corporation | Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties |
US8039500B2 (en) | 2006-12-29 | 2011-10-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
TW200902019A (en) | 2007-04-26 | 2009-01-16 | Ono Pharmaceutical Co | Dicyclic heterocyclic compound |
WO2009008552A1 (en) | 2007-07-11 | 2009-01-15 | Taisho Pharmaceutical Co., Ltd. | 8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives |
WO2009144632A1 (en) | 2008-05-30 | 2009-12-03 | Pfizer Limited | Novel compounds |
US7932256B2 (en) | 2008-07-31 | 2011-04-26 | Bristol-Myers Squibb Company | (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity |
CN102105149A (zh) | 2008-07-31 | 2011-06-22 | 百时美施贵宝公司 | 作为促肾上腺皮质激素释放因子受体活性调节剂的取代的氨基甲酸酯衍生物 |
US7994203B2 (en) | 2008-08-06 | 2011-08-09 | Novartis Ag | Organic compounds |
US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
WO2010062718A1 (en) | 2008-11-03 | 2010-06-03 | Synthes Usa, Llc | Adjustable rod assembly |
WO2010096426A2 (en) | 2009-02-20 | 2010-08-26 | Emory University | Compounds, compositions, methods of synthesis, and methods of treatment |
HUP0900267A2 (en) | 2009-04-30 | 2011-03-28 | Sanofi Aventis | Process for preparing of thiazole amines and intermediates thereof |
EP2487177A1 (en) | 2009-10-08 | 2012-08-15 | Eisai R&D Management Co., Ltd. | Pyrazoloxazole compound |
AR078521A1 (es) | 2009-10-08 | 2011-11-16 | Eisai R&D Man Co Ltd | Compuesto pirazolotiazol |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
US20120295942A1 (en) | 2010-02-01 | 2012-11-22 | Nicholas James Devereux | Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists |
JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
RU2699546C2 (ru) | 2012-04-13 | 2019-09-06 | Эпизайм, Инк. | Комбинированная терапия для лечения рака |
WO2013160317A2 (en) | 2012-04-23 | 2013-10-31 | Holsboermaschmeyer Neurochemie Gmbh | Crhr1 antagonists for use in the treatment of patients having crh overactivity |
EP2841595A2 (en) * | 2012-04-23 | 2015-03-04 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Genetic predictors of response to treatment with crhr1 antagonists |
EP3096756B1 (en) | 2014-01-21 | 2024-06-12 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
WO2016065177A1 (en) | 2014-10-22 | 2016-04-28 | The Trustees Of The University Of Pennsylvania | Method of treating depression and other stress related disorders |
CN107438606B (zh) | 2015-02-06 | 2020-09-18 | 纽罗克里生物科学有限公司 | [9,10-二甲氧基-3-(2-甲基丙基)-1h,2h,3h,4h,6h,7h,11bh-吡啶并-[2,1-a]异喹啉-2-基]甲醇及与其相关的化合物、组合物和方法 |
US20180119221A1 (en) | 2015-04-02 | 2018-05-03 | Hmnc Value Gmbh | Method of Treatment Using Genetic Predictors of a Response to Treatment with CRHR1 Antagonists |
WO2018012066A1 (ja) * | 2016-07-14 | 2018-01-18 | 株式会社コナミデジタルエンタテインメント | ゲームシステム、端末装置及びプログラム |
EP3548035A4 (en) | 2016-11-30 | 2020-07-22 | Case Western Reserve University | COMBINATIONS OF 15 PGDH INHIBITORS WITH CORTICOSTEROIDS AND / OR TNF INHIBITORS AND USES THEREOF |
WO2018219804A1 (en) | 2017-06-02 | 2018-12-06 | Bayer Pharma Aktiengesellschaft | Self-microemulsifying drug delivery systems |
JP7285222B2 (ja) | 2017-08-14 | 2023-06-01 | スプルース バイオサイエンシズ インコーポレイテッド | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
CN110996943A (zh) | 2017-08-14 | 2020-04-10 | 云杉生物科学公司 | 促肾上腺皮质激素释放因子受体拮抗剂 |
EP3784233B1 (en) | 2018-04-27 | 2024-06-05 | Spruce Biosciences, Inc. | Methods for treating testicular and ovarian adrenal rest tumors |
MA54395A (fr) | 2018-12-07 | 2022-03-16 | Neurocrine Biosciences Inc | Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale |
EP3986416A4 (en) | 2019-07-19 | 2023-06-28 | Spruce Biosciences, Inc. | Methods of treating congenital adrenal hyperplasia |
WO2021062246A1 (en) | 2019-09-27 | 2021-04-01 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
AR120649A1 (es) | 2019-12-04 | 2022-03-09 | Neurocrine Biosciences Inc | Antagonistas del receptor de crf y métodos de uso |
WO2021252669A1 (en) | 2020-06-10 | 2021-12-16 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia |
EP4203964A1 (en) | 2020-08-26 | 2023-07-05 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
-
2015
- 2015-01-21 EP EP15702917.4A patent/EP3096756B1/en active Active
- 2015-01-21 NZ NZ722122A patent/NZ722122A/en unknown
- 2015-01-21 RU RU2016133972A patent/RU2718918C2/ru active
- 2015-01-21 CN CN201580005270.4A patent/CN106102740A/zh active Pending
- 2015-01-21 US US15/113,362 patent/US20170020877A1/en not_active Abandoned
- 2015-01-21 IL IL296683A patent/IL296683B2/en unknown
- 2015-01-21 CN CN202010134003.XA patent/CN111228274A/zh active Pending
- 2015-01-21 MX MX2016009499A patent/MX2016009499A/es unknown
- 2015-01-21 AU AU2015209452A patent/AU2015209452C1/en active Active
- 2015-01-21 WO PCT/US2015/012315 patent/WO2015112642A1/en active Application Filing
- 2015-01-21 CA CA2936974A patent/CA2936974A1/en active Pending
- 2015-01-21 BR BR112016016975-1A patent/BR112016016975B1/pt active IP Right Grant
- 2015-01-21 CA CA3155599A patent/CA3155599A1/en active Pending
- 2015-01-21 KR KR1020167022375A patent/KR102258522B1/ko active IP Right Grant
- 2015-01-21 JP JP2016565135A patent/JP6585625B2/ja active Active
- 2015-01-21 KR KR1020217015795A patent/KR20210064407A/ko not_active Application Discontinuation
-
2016
- 2016-07-14 IL IL246783A patent/IL246783B/en unknown
- 2016-07-21 MX MX2021012539A patent/MX2021012539A/es unknown
- 2016-07-21 MX MX2022000080A patent/MX2022000080A/es unknown
-
2018
- 2018-12-20 US US16/227,127 patent/US10905690B2/en active Active
-
2019
- 2019-03-11 JP JP2019043466A patent/JP6936825B2/ja active Active
-
2020
- 2020-06-09 JP JP2020099865A patent/JP7104743B2/ja active Active
- 2020-07-20 AU AU2020207774A patent/AU2020207774B2/en active Active
- 2020-10-20 US US17/074,845 patent/US11730739B2/en active Active
-
2021
- 2021-08-04 US US17/393,553 patent/US11311544B2/en active Active
- 2021-09-29 IL IL286782A patent/IL286782A/en unknown
- 2021-11-12 JP JP2021184620A patent/JP2022010260A/ja not_active Withdrawn
-
2022
- 2022-10-31 AU AU2022263460A patent/AU2022263460A1/en active Pending
-
2023
- 2023-06-29 IL IL304134A patent/IL304134A/en unknown
- 2023-07-14 US US18/222,011 patent/US20240058342A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022000080A (es) | Antagonistas de receptor del factor de liberacion de corticotropina (crf1) para el tratamiento de hiperplasia adrenal congenita. | |
MX2020014300A (es) | Compuestos heterociclicos utiles en el tratamiento de enfermedades. | |
IL287889A (en) | Administration of transgenic t cells for the treatment of central nervous system cancer | |
MX2015011132A (es) | Moduladores policiclicos del receptor de estrogenos y sus usos. | |
MX2015016171A (es) | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. | |
MX2015017655A (es) | Modulador de receptores de estrogeno y uso del mismo. | |
PH12015501738A1 (en) | Androgen receptor modulators and uses thereof | |
NI201500093A (es) | Modulador del receptor de andrógenos y usos de este | |
PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
MX2016011636A (es) | Combinaciones terapeuticas con moduladores de receptor de estrogeno. | |
IL272095A (en) | 17-alpha-21-cortexolone diesters for use in the treatment of tumors and as glucocorticoid receptor modulators | |
TWD170334S (zh) | 垃圾桶之部分 | |
SA516370641B1 (ar) | مركبات حلقية غير متجانسة وطرق لاستخدامها | |
TWD175341S (zh) | 馬桶座之部分 | |
MX2017007707A (es) | Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama. | |
EP3145516A4 (en) | Methods and compositions for treating malignancies with dendritic cells | |
AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
HK1248126A1 (zh) | 糖皮質激素受體拮抗劑聯合糖皮質激素用於治療腎上腺功能不全 | |
MY175326A (en) | Product and method for treating diarrhea | |
MX361407B (es) | Formulaciones de liberacion controlada de hidrocortisona. | |
MX2015016603A (es) | Composiciones de corticosteroides. | |
MX2016011706A (es) | Formulaciones de progesterona. | |
AU355858S (en) | Castor brace for ladder | |
TR201406300A2 (tr) | Madde bağımlılığının tedavisine yönelik oluşturulmuş bir formülasyon. | |
EP3161696A4 (en) | Systems and methods for delivering remedy frequencies |